PNC-27

P53 Derived Anticancer PeptideRx: ResearchCompound: Investigational

Also known as: HDM-2 binding peptide, p53(12-26), PNC27, Pronco-27

Educational Only — Not medical advice. Consult a qualified clinician before using any peptide.

Source PNC-27 at Peptiology

Save 10% with code PEPTI-BOSSRABBIT-10

Shop Now & Save 10% →

Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.

Summary

Synthetic peptide derived from p53 residues 12-26 designed to target HDM-2 overexpressed on cancer cell surfaces, inducing selective cancer cell death without harming normal cells

Mechanism of Action

Binds to HDM-2 (human double minute 2) on cancer cell membranes, forming pores and inducing membranolysis; releases p53 from HDM-2 inhibition, restoring p53-mediated apoptosis

Routes of Administration

IntraperitonealIntravenous

Goals & Uses

  • cancer treatmentOncologyModerate
  • p53 restoration therapyTargeted TherapyModerate

Contraindications

No contraindications recorded yet.

Adverse Effects

  • Injection site reactionsLocalUnknown
  • off-target membranolysisSystemicRare

Drug Interactions

No drug interactions recorded yet.

Population Constraints

  • p53-mutant cancersTumor GeneticsRelative
  • HDM-2-negative cancersTumor BiologyAbsolute

Regulatory Status

  • European UnionUnapprovedNo EMA approval
  • United StatesUnapprovedNo FDA approval; not listed in clinicaltrials.gov with active enrollment

Not approved for clinical use; preclinical studies ongoing; early-phase clinical trials reported in literature but not registered in major trial databases

Evidence & Sources

No sources recorded yet.

Frequently Asked Questions

What is PNC-27?

Synthetic peptide derived from p53 residues 12-26 designed to target HDM-2 overexpressed on cancer cell surfaces, inducing selective cancer cell death without harming normal cells

What is PNC-27 used for?

PNC-27 is educationally associated with: cancer treatment, p53 restoration therapy. Educational only — not medical advice.

How is PNC-27 administered?

Recorded routes of administration: Intraperitoneal, Intravenous.

What are the potential side effects of PNC-27?

Reported adverse effects include: Injection site reactions, off-target membranolysis. This list is not exhaustive — consult a qualified clinician.